


REGIO-SPECIFIC TOTAL SYNTHESIS OF (±)-2-HYDROXYAKLAVINONE

Hiroshi Tanaka, Takeo Yoshioka, Yasutaka Shimauchi, Akihiro Yoshimoto and Tomoyuki Ishikura  
 Sanraku-Ocean Co., Ltd., Central Research Laboratories,  
 Johnan, Fujisawa 251, Japan

Hiroshi Naganawa, Tomio Takeuchi and Hamao Umezawa  
 Institute of Microbial Chemistry,  
 Kamiosaki, Shinagawa, Tokyo 141, Japan


**Summary:** The tricyclic quinone 8 was successfully synthesized from naphthazalin, and the total synthesis of (±)-2-hydroxyaklavinone via 8 was accomplished in an overall yield of about 18% through the regio-controlled route.

As do many aclacinomycin-type anthracyclines<sup>1</sup>, 2-hydroxyaclacinomycin A (1)<sup>2</sup> (which was produced from naturally occurring 2-hydroxyaklavinone (2)<sup>3</sup> by microbial glycosidation) has a potent anticancer activity against L1210 leukemia in mice. Our attention has, therefore, been focused on the chemical synthesis of this and related antibiotics. Recently, the total synthesis of akalavone (4)<sup>4</sup> (an aglycone of the clinically important antitumor agent aclacinomycin A (3)<sup>5</sup>) has been achieved by several efficient processes<sup>6</sup>, but no synthesis of 2 has been reported yet. We now describe the total synthesis of racemic 2 in 14 steps starting from naphthazalin.




In order to construct 11-deoxy anthracyclinone, we made the versatile synthon (8), an ABC-ring unit, as described below. Diels-Alder reaction between naphthazalin and 1-acetoxy-2-ethyl-1,3-butadiene<sup>7</sup> in refluxing CH<sub>2</sub>Cl<sub>2</sub> for 3 hr gave the adduct 5 (mp 144 ~ 145°C, 99%). Successive reduction of 5 (2 equiv. of NaBH<sub>4</sub>, THF, 0°C) proceeded regioselectively to afford

the olefinic triol 6 (mp 158 ~159°C, 95%). The olefinic bond of 6 was readily hydrogenated over  $\text{PtO}_2$  in  $\text{EtOAc}$  at atmospheric pressure, giving 7 (mp 148 ~149°C, 95%). Conversion of 7 into 8 was the key step, involving both dehydration and oxidation. Attempts to dehydrate the benzylic alcohol of 7 by treatment with acid or base failed, but trifluoroacetylation (i. 5 equiv. of  $(\text{CF}_3\text{CO})_2\text{O}$ , pyr., 0°C, 0.5 hr. ii. addition of 10 equiv. of triethylenediamine, 50°C, 0.5 hr) gave an aromatized intermediate. This material was dissolved in benzene and subjected to air-oxidation in the presence of triethylamine to provide the tricyclic quinone 8<sup>8</sup> (mp 141 ~142°C) in 85% yield.




The quinone 8 having only one peri-hydroxy group was expected to be a regio-controlled dienophile on Diels-Alder reaction as described previously by Kelly<sup>9</sup> and others<sup>10</sup>. Indeed, the coupling between 8 and 1-methoxy-1,3-bis(trimethylsilyloxy)butadiene<sup>11</sup> in  $\text{CH}_2\text{Cl}_2$ , followed by acid treatment (0.1N  $\text{HCl}/\text{MeOH}$ ) gave a 79:21 mixture of the desired tetracyclic compounds 9a and 9b in 92% combined yield. Crystallization of the mixture from  $\text{CHCl}_3$  afforded pure 9a (mp 278 ~280°C) and it was deacetylated with 5 equiv. of  $\text{NaOMe}$  in  $\text{THF}/\text{MeOH}$  into tetraol 10 (mp 256 ~259 °C, 100%). The tetraol 10 was oxidized with Jones reagent in  $\text{Me}_2\text{CO}$  to the key intermediate ketone 11<sup>12</sup> (mp 274 ~277°C, 96%).

Acetylation of 11 (i.  $\text{Ac}_2\text{O}/\text{catalytic } 60\% \text{ HClO}_4, \text{CH}_2\text{Cl}_2$ . ii. addition of pyr.) provided the tetraacetate 12 (mp 205 ~207°C, 96%). After ozonolysis of 12, 13 was subjected to Arndt-Eistert reaction (i. excess  $\text{SOCl}_2, \text{CH}_2\text{Cl}_2$ , reflux, 5 hr. ii.  $\text{CH}_2\text{N}_2, \text{Et}_2\text{O}, 0^\circ\text{C}, 0.5 \text{ hr}$ . iii.  $\text{MeOH}/\text{Ag}_2\text{O}, 60^\circ\text{C}, 1 \text{ hr}$ . under  $\text{N}_2$  in all reactions. iv. chromatographic separation) to afford 14a (mp 159 ~165°C, 8.3%) and 14b (mp 204 ~208°C, 46%).



The compound 14a (or 14b) was cyclized and deacetylated with 5 equiv. of Triton B(OH)<sup>6e</sup> in MeOH at -20°C for 3 days, to provide a 72:28 mixture of (±)-7-deoxy-2-hydroxyaklavinone 15a<sup>13</sup> (mp 244 ~246°C) and its C-10 epimer 15b in 94.6% combined yield. The diastereomeric mixture could be separated on silica gel plates (15a: R<sub>f</sub>=0.66, 15b: R<sub>f</sub>=0.50) using Et<sub>2</sub>O as an eluant. Base treatment of 15b (3.5 equiv. of DBU, CH<sub>2</sub>Cl<sub>2</sub>, 23°C, 18 hr) gave a 2:3 equilibrium mixture (by NMR analysis) of 15a and 15b. The yield of 15a was enhanced to 77% after one such equilibration.



As direct hydroxylation of 15a at the C-7 position resulted in poor yield, 15a was selectively protected as the monoacetate 16 (i. 2 equiv. of B(OH)<sub>3</sub>/excess Ac<sub>2</sub>O, THF, rt, 4 hr. ii. addition of pyr., 0.25 hr, 98%). Subsequent homolytic bromination of 16 (2 equiv. of Br<sub>2</sub>/AIBN, reflux, 1 hr) followed by solvolysis (1:1 H<sub>2</sub>O/THF, rt, 1 hr)<sup>6a</sup> provided (±)-2-O-acetyl-2-hydroxyaklavinone 17 (mp 229 ~232°C, 90%) in 100% stereospecific yield.

Finally, deacetylation of 17 (1.5 equiv. of NaOMe/MeOH, 0°C, 0.2 hr, under N<sub>2</sub>, 100%) afforded (±)-2-hydroxyaklavinone<sup>14</sup> (mp ~220°C) which was identical with natural 2-hydroxyaklavinone (2)<sup>15</sup> by mp, IR, UV, NMR and TLC.

The regio- and stereo-selective glycosidation of 2-hydroxyaklavinone with the trisaccharide RDC has been reported<sup>16</sup>. Since we have described the synthesis of the aglycone moiety in this communication, a total synthesis of 2-hydroxyaklavinone has been accomplished.

## References and notes

1. T. Oki, I. Kitamura, Y. Matsuzawa, N. Shibamoto, T. Ogasawara, A. Yoshimoto, T. Inui, H. Naganawa, T. Takeuchi, H. Umezawa, J. Antibiotics, **32**, 801 (1979).
2. T. Oki, A. Yoshimoto, Y. Matsuzawa, T. Takeuchi, H. Umezawa, J. Antibiotics, **34**, 916 (1981).
3. a) A. Yoshimoto, Y. Matsuzawa, T. Oki, T. Takeuchi, H. Umezawa, J. Antibiotics, **34**, 951 (1981). b) Y. Matsuzawa, A. Yoshimoto, N. Shibamoto, H. Tobe, T. Oki, H. Naganawa, T. Takeuchi, H. Umezawa, J. Antibiotics, **34**, 959 (1981).
4. D. Tresselt, K. Eckardt, J. Tax, Tetrahedron, **31**, 613 (1975).
5. T. Oki, I. Kitamura, A. Yoshimoto, Y. Matsuzawa, N. Shibamoto, T. Ogasawara, T. Inui, A. Takamatsu, T. Takeuchi, T. Masuda, M. Hamada, H. Suda, M. Ishizuka, T. Sawa, H. Umezawa, J. Antibiotics, **32**, 791 (1979).
6. a) A. S. Kende, J. P. Rizzi, J. Am. Chem. Soc., **103**, 4247 (1981). b) B. A. Pearlman, J. M. McNamara, I. Hasan, S. Hatakeyama, H. Seizaki, Y. Kishi, J. Am. Chem. Soc., **103**, 4248, (1981). c) P. N. Confalone, G. Pizzolato, J. Am. Chem. Soc., **103**, 4251 (1981). d) T. Li, Y. L. Wu, J. Am. Chem. Soc., **103**, 7007 (1981). e) R. K. Boeckmann, Jr., F. -W. Sun, J. Am. Chem. Soc., **104**, 4604 (1982). f) J. M. McNamara, Y. Kishi, J. Am. Chem. Soc., **104**, 7371 (1982).
7. Prepared by enol-acetylation of 2-ethylcrotonaldehyde with isopropenylacetate and catalytic TsOH, bp 42°C/8mm, 82% yield.
8.  $\tilde{\nu}_{\max}^{\text{KBr}}$  1720, 1660, 1630  $\text{cm}^{-1}$ ; NMR( $\text{CDCl}_3$ )  $\delta$ 2.07(s, 3H), 6.90(s, 2H), 7.62(s, 1H), 12.34(s, 1H).
9. T. R. Kelly, J. W. Gillard, R. N. Gorner, Jr., J. M. Lyding, J. Am. Chem. Soc., **99**, 5513 (1977).
10. a) R. K. Boeckmann, Jr., T. M. Dolak, K. O. Culos, J. Am. Chem. Soc., **100**, 7098 (1978). b) B. M. Trost, J. Ippen, W. C. Vladuchick, J. Am. Chem. Soc., **99**, 8116 (1977).
11. K. Yamamoto, S. Suzuki, J. Tsuji, Chem. Lett., 649 (1978).
12.  $\tilde{\nu}_{\max}^{\text{KBr}}$  1695, 1610  $\text{cm}^{-1}$ ; NMR( $\text{CDCl}_3$ )  $\delta$ 6.56(d, J=2, 1H), 7.19(d, J=2, 1H), 8.22(s, 1H).
13.  $\tilde{\nu}_{\max}^{\text{KBr}}$  1720, 1665, 1615  $\text{cm}^{-1}$ ; NMR(1:1  $\text{CDCl}_3/\text{CD}_3\text{OD}$ )  $\delta$ 1.08(t, J=7, 3H), 1.3~3.2(m, 6H), 3.73(s, 3H), 3.95(bs, 1H), 6.55(d, J=2, 1H), 7.18(d, J=2, 1H), 7.56(s, 1H).
14. ( $\pm$ )-**2**:  $\lambda_{\max}^{\text{KBr}}$  90%MeOH 226, 256, 270, 292, 440 nm;  $\tilde{\nu}_{\max}^{\text{KBr}}$  1730, 1725(sho), 1675, 1620  $\text{cm}^{-1}$  (authentic **2**: 1725, 1675, 1620  $\text{cm}^{-1}$ ); NMR(1:1  $\text{CDCl}_3/\text{CD}_3\text{OD}$ )  $\delta$ 1.10(t, J=7, 3H), 1.65(m, 2H), 2.22(bd, J=15, 1H), 2.50(dd, J=4.5, 15, 1H), 3.72(s, 3H), 4.10(s, 1H), 5.31(dd, J=1.5, 4.5, 1H), 6.60(d, J=2, 1H), 7.22(d, J=2, 1H), 7.60(s, 1H).
15. Recrystallized from MeOH/ $\text{CHCl}_3$  (mp ~220°C, dec.) and the spectral data were obtained for the identification.
16. H. Tanaka, T. Yoshioka, A. Yoshimoto, Y. Shimauchi, T. Ishikura, T. Takeuchi, H. Umezawa, J. Antibiotics, **36**, 601 (1983).

(Received in Japan 16 April 1984)